Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)

NCT ID: NCT00779740

Last Updated: 2024-08-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 102 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-02-01
• Study Completion Date: 2005-04-01

Brief Summary

This is a multicenter, open-label, randomized, parallel group comparison study to verify the clinical equivalency of the old formulation (50 mcg as mometasone furoate [MF] in 50 μL of solution per spray) to the new formulation (50 mcg as MF in 100 μL of solution per spray) in patients with perennial allergic rhinitis.

Conditions

Rhinitis, Allergic, Perennial

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

New Formulation Group

Group Type: EXPERIMENTAL

mometasone furoate

Intervention Type: DRUG

The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.

Old Formulation Group

Group Type: ACTIVE_COMPARATOR

mometasone furoate

Intervention Type: DRUG

The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.

Interventions

mometasone furoate

The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.

Intervention Type: DRUG

mometasone furoate

The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.

Intervention Type: DRUG

Other Intervention Names

Nasonex; SCH 32088; Nasonex; SCH 32088

Eligibility Criteria

Inclusion Criteria

• Patients of mongoloid race residing in Japan who satisfy all of the following criteria:

• Patients having symptoms of perennial allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining informed consent and during the pretreatment observation period.
• Patients with a positive skin reaction test or specific IgE antibody quantitation, and with a positive cytological examination of nasal discharge (eosinophils) or nasal challenge test.
• Outpatients who are at least 16 years of age at the time of informed consent obtained.
• Male or female.
• Patients who have the ability to give written informed consent (informed consent of the guardian must also be obtained for patients younger than 20 years).
• Patients who can keep nasal allergy diary without fail.

Exclusion Criteria

• Patients with coexisting tuberculous disease or lower respiratory tract infection, or patients who, at the time of registration, have acute upper respiratory tract infection, acute pharyngitis, acute amygdalitis etc.
• Patients with coexisting infections or systemic mycosis for which there are no effective antibiotics.
• Patients with unhealed nasal septum ulcers, nasal surgery scar, or nasal trauma.
• Patients with a history of hypersensitivity to steroids or mometasone furoate.
• Patients who are pregnant or nursing or who may be pregnant and patients or patients' partners who desire to become pregnant during the study period.
• Patients with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension or other serious coexisting diseases and whose general condition is poor.
• Patients also allergic to pollen and the pollen release season occurs during the study period.
• Patients with vasomotor rhinitis or eosinophilic rhinitis.
• Patients with a nasal condition which may interfere with efficacy evaluation of the investigational product.
• Patients who develop disease affecting nasal symptoms during the pretreatment observation period, i.e., during the 7 days before actual registration.
• Patients who are participating or have participated in a clinical trial of another investigational drug within 120 days (4 months) before the day of the informed consent for this study.
• Patients for whom the period of discontinuation of previous treatment effective for allergic rhinitis before the start of the investigational product administration is not sufficient or who cannot avoid its use.
• Patients receiving specific desensitization therapy or nonspecific modulation therapy or who had just discontinued such therapies within 90 days (3 months) before providing consent to this study (unless such therapies are ongoing as maintenance therapy and had been started 180 days [6 months] or more before consent to this study).
• Other patients judged inappropriate for study by the investigator or subinvestigator.

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Organon and Co

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

References

T. Ishikawa et. al; Practica otologica. Suppl.123 Page1-18 (2008.12) -Japanese language journal

Reference Type: RESULT

Other Identifiers

JPC-04-342-41

Identifier Type: -

Identifier Source: secondary_id

P04419

Identifier Type: -

Identifier Source: org_study_id